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Abstract.  Scatchard  analyses of the binding  of trans- 
forming growth factor-beta (TGF-beta)  to a  wide vari- 
ety of different cell types in culture revealed the 
universal  presence of high affinity (Kd  =  1-60 pM) 
receptors  for TGF-beta on every cell type assayed,  in- 
dicating  a  wide potential  target range for TGF-beta ac- 
tion.  There was a  strong  (r  =  +0.85)  inverse relation- 
ship between the receptor affinity and the number  of 
receptors expressed per cell,  such that at low TGF- 
beta concentrations,  essentially all cells bound a  simi- 
lar number of TGF-beta molecules per cell.  The bind- 
ing of TGF-beta to various cell types was not altered 
by many agents that affect the cellular response to 
TGF-beta,  suggesting  that modulation  of TGF-beta 
binding  to its receptor may not be a  primary  control 
mechanism  in TGF-beta action.  Similarly,  in vitro 
transformation  resulted in only relatively small 
changes  in the cellular binding  of TGF-beta,  and  for 
those cell types that  exhibited ligand-induced  down- 
regulation  of the receptor,  down-regulation  was not ex- 
tensive.  Thus the strong conservation  of binding  ob- 
served between cell types is also seen within  a given 
cell type under a  variety of conditions,  and receptor 
expression  appears to be essentially constitutive.  Fi- 
nally,  the biologically inactive form of TGF-beta, 
which constitutes >98%  of autocrine  TGF-beta 
secreted by all of the twelve different cell types as- 
sayed, was shown to be unable to bind to the receptor 
without prior activation in vitro.  It is proposed that 
this  may prevent premature  interaction  of autocrine 
ligand and  receptor in the Golgi apparatus. 
T 
RANSFORMING  growth  factor-beta  (TGF-beta) l  was 
originally characterized by its ability to induce reversi- 
ble phenotypic transformation of non-neoplastic indi- 
cator cells (36, 41). It was proposed that transformed cells 
might have a selective growth advantage by secreting and re- 
sponding to such growth factors in an autocrine fashion (13, 
50,  52).  However,  TGF-beta  has  since  been isolated  and 
purified from a variety of normal tissues as well as neoplastic 
sources (43), suggesting a role for TGF-beta in normal cell 
physiology. The protein from all these sources is an acid- 
stable,  disulfide-linked  homodimer  with  an Mr of 25,000, 
and the sequence is highly conserved between species (14). 
Evidence is accumulating  that TGF-beta is an important 
regulator of growth and differentiation for a wide variety of 
both normal  and transformed  cell types.  It stimulates  the 
anchorage-independent growth of various normal fibroblas- 
tic cells,  is mitogenic  for certain  fibroblasts in vitro,  and 
stimulates wound healing,  fibroblast proliferation,  and an- 
giogenesis in vivo (for a review, see reference 51). However, 
it inhibits the in vitro proliferation of mitogenically stimu- 
lated B and T lymphocytes (23, 24), various normal epithe- 
lial cell types (11, 35, 37, 49, 55), and of a number of human 
1. Abbreviations used in this paper: EGF, epidermal growth factor; HaSV, 
Harvey sarcoma virus; MoSV, Moloney sarcoma virus; NRK,  normal rat 
kidney;  PDGF,  platelet-derived  growth factor;  TGF, transforming growth 
factor. 
tumor  lines  (37, 40).  This  raises  the  possibility  that  the 
growth of certain normal cells may be regulated in a negative 
autocrine manner by TGF-beta, with lesions in this negative 
control  process  leading  to  uncontrolled  cell  proliferation 
(50). In addition to its effects on cell growth, TGF-beta is a 
potent inducer of differentiation for normal bronchial epithe- 
lial cells (35) and chondrocytes (48), while it inhibits the ex- 
pression of differentiated function in preadipocytes (21),  B 
and T  lymphocytes (23, 24),  natural  killer cells (44),  and 
myocytes (16). 
A  unique  high  affinity receptor  for TGF-beta has  been 
identified on normal rat kidney (NRK) cells (17) and other 
fibroblastic  and  epithelial  cell  lines  (6,  17,  34,  54).  The 
receptor  is  a  disulfide-linked  glycosylated  dimer  of  Mr 
,~560,000 (15, 32), and preliminary  evidence suggests that 
the TGF-beta receptor differs from the receptors for many 
other growth factors, in that it does not show ligand-induced 
clustering,  nor does it appear to autophosphorylate (15). 
In this paper we have examined the distribution and modu- 
lation  of the TGF-beta receptor on a  wide variety of cell 
types. We find the TGF-beta receptor to be universally ex- 
pressed, and we demonstrate a novel inverse relationship be- 
tween receptor number and affinity,  such that at low TGF- 
beta concentrations all cell types bind essentially the same 
number of TGF-beta molecules per cell. This functional con- 
servation of binding is also preserved within a given cell type 
© The Rockefeller University Press, 0021-9525/87/08/965/I 1 $2.00 
The Journal of Cell Biology, Volume 105, August 1987 965-975  965 under various conditions. Thus many factors that modulate 
the cellular response to TGF-beta appear to have no effect on 
the binding of TGF-beta to its receptor, there is little or no 
ligand-induced receptor down-regulation, and the effects of 
in vitro transformation on TGF-beta binding are far less ex- 
tensive than is  observed  for other growth factors  such as 
epidermal growth factor (EGF) and platelet-derived growth 
factor  (PDGF)  (9,  53).  Thus  binding  of TGF-beta  to  its 
receptor appears to be essentially unmodulated. Finally, we 
show that the biologically latent form of TGF-beta is unable 
to bind to the receptor, and we suggest that this may prevent 
premature association of ligand and receptor in the Golgi ap- 
paratus. 
Materials and Methods 
Cells 
Pulmonary  artery  endothelial cells,  normal  human bronchial  epithelial 
cells, mesothelial cells, and fibroblasts were all low passage explant cultures 
established and propagated in culture as described elsewhere (28-30, 47). 
Human tonsillar T lymphoeytes were prepared by rosetting tousillar mono- 
nuclear cells and activated as described previously (24). All remaining cell 
lines and strains were grown in DME (4.5 g/liter glucose) containing 5% 
FBS (Gibco, Grand Island, NY), with the exception of the NRK 49F cells 
which were grown in the same medium but one that contained 10% calf se- 
rum (MA Bioproducts, Walkersville, MD) in place of FBS. 
lodination of TGF-Beta 
Pure TGF-beta isolated from human platelets (5) was iodinated to high 
specific activity (2 i.tCi/pmol;  80 p.Ci/~tg), with essentially full retention of 
biological activity, using a modified chloramine T method (17). Typically 
>99 % of the iodinated peptide was precipitable by TCA immediately after 
iodination, of which 95 % was capable of specific binding to the receptor. 
The  percentage of  nSI-TGF-beta  capable  of specific binding decreased 
linearly with time by *0.35 %/d thereafter, and the measured free TGF-beta 
concentration was routinely corrected to take this into account. 
Binding Assay 
For cells that grow attached to tissue culture plates, a solid-phase monolayer 
assay was used, while for the T lymphocytes a suspension binding assay was 
used. The monolayer assay was a modification of that described by Frolik 
et al.  (17). Cells were seeded in their normal growth medium at  m1OS 
cells/well in 24-well cluster plates and allowed to grow for 24 h, such that 
at the time of assay they were somewhat subconfluent and still actively 
growing. The monolayers were then washed with 1 mi/well of  binding buffer 
(DME containing 0.1% BSA and 25 mM Hepes, pH 7.4) and incubated in 
this medium for 2 h at 37°C to allow dissociation  of  bound endogenous TGF- 
beta.  Control experiments shox~t this procedure resulted in removal of 
85-95 % of pre-bound TGF-beta. After washing, cells were incubated in 0.2 
mi binding buffer containing 1-500 pM mI-TGF-beta for 2 h at 22°C in a 
5 % CO2 atmosphere. Nouspecific binding was determined in the presence 
of 10 nM unlabeled TGF-beta. At the end of the incubation, the free ligand 
concentration was determined from the medium counts, and the cells were 
then washed four times in ice-cold Hanks'-buffered saline (Gibco) contain- 
ing 0.1% BSA. Bound counts were solubilized by the addition of solubiliza- 
tion buffer (1% Triton X-100, 10% glycerol, 20 mM Hepes, pH 7.4).  This 
solubilization protocol was  used instead of the usual  NaOH  or  formic 
acid-based extraction procedures because it reduced the recovery of ligand 
nonspecifically bound to the plastic ('~30% of input counts) rather than to 
the cells. Typically,  the level of nonspecitic binding ranged from "o5 % of 
total binding at low free ligand concentrations (I pM) to >50% of total bind- 
ing at high ligand concentrations (>200 pM), when the receptor was satu- 
rated.  The clam specifically bound generally ranged from 100 to  10,000 
cpm/well over the saturation curve. Cell number was determined on wells 
treated identically up to the solubilization step. TGF-beta receptors on lym- 
phocytes in suspension were assayed as described previously (24), except 
that the binding buffer used was MEM without bicarbonate, containing 0.1% 
BSA and 25 mM Hepes, pH 7.4. Binding data were analyzed according to 
the method of Scatchard (46). 
All binding assays were performed at 22°C for comparative purposes 
since many of  the cell types assayed detached from the culture plates during 
prolonged serum-free incubation at 4°C. The decrease in TCA precipitabil- 
ity of TGF-beta in the medium after 2 h incubation at 22°C was usually 
~3%, indicating minimal ligand degradation at this temperature. Control 
experiments on A549 human lung carcinoma cells confirmed that there was 
no ligand-induced receptor down-regulation at this temperature. Thus use 
of Scatehard analysis, which assumes equilibrium between free and bound 
ligand,  is probably valid for the binding data obtained under these ex- 
perimental conditions, and at very least gives useful comparative values for 
the Kd and receptor number per cell. Receptors could reliably be detected 
down to 1,000 receptors/cell for the monolayer assay and 100 receptors/cell 
for the suspension assay. In addition, the assay was reproducible. For exam- 
ple, assay of four different lots of normal human bronchial epithelial cells 
from different donors, using four different batches of ~25I-TGF-beta gave 
mean receptor parameters of 12  -k 2 pM for the Ka, and 10,000 +  3,000 
for the number of receptors, representing an interassay variation of <+20 % 
for the affinity and +30% for the receptor number. Some of this variation 
could be accounted for by individual differences rather than interassay varia- 
tion. Thus for the A549 human lung carcinoma line, three separate assays 
using three different batches of iodinated TGF-beta gave a mean Kd of 15 
+  3 pM, and a receptor number of 10000  +  1,400 receptors/cells, corre- 
sponding to an interassay variation of oniy 5:17% for the affinity and +14% 
for the receptor number. Nevertheless, where receptor parameters were to 
be compared on matched pairs of cell types (e.g., transformed vs. untrans- 
formed), the cells were assayed on the same day, under identical conditions. 
Collection of Conditioned Media 
Cells were grown to ~80% confluence in Falcon T175 flasks in DME/5 % 
FBS and were then washed three times at 2-h intervals with serum-free 
DME. The cells were then incubated for 18 h in serum-free DME and this 
medium was discarded. Finally, cells were incubated for 24 h in 40 ml/flask 
fresh serum-free DME and this medium was collected for processing. For 
the Myc-I cells, 1% Nutridoma-SP (Boehringer-Mannheim Biochemicals, 
Indianapolis, IN) was included with the DME and this improved cell attach- 
ment and viability.  Nutridoma does not contain any assayable TGF-beta 
(data not shown). The cell number and viability (always >80%) at the end 
of the collection period were determined. At this point, conditioned media 
were treated in one of two ways. 
Acid Dialysis. Immediately after collection, the medium was clarified by 
ultracentrifugation for 1 h at 100,000 g~.  Clarified medium was dialyzed 
extensively (Spectrapor dialysis tubing, 3,000 mw cutoff) against 1 M acetic 
acid, lyophilized, and resuspended in  1/lOth vol  1 M  acetic acid and re- 
dialyzed. This second dialysis step appeared to be necessary to remove re- 
sidual salt and other dialyzable components that interfered with the quan- 
titative radioreceptor assay. Typically samples were then prepared for the 
radioreceptor assay by lyophilizing 1-2 ml with 1/5 vol 1 M acetic acid con- 
taining  0.1% BSA and  resuspending the lyophilized powder in binding 
buffer.  The overall recovery of TGF-beta was 40%, and the final data were 
corrected by this factor. 
Transient Acidification. BSA was added to neutral conditioned medium 
to a  final concentration of 0.1%,  before clarification of the medium by 
ultracentrifugation in siliconized tubes at 100,000 g,v for 1 h. Recovery of 
TGF-beta after this step was 90%. Aliquots of the medium were then acidi- 
fied by addition of HCI  (final pH  3.2),  incubated for  1 h  at 4°C,  and 
reneutralized by the addition of 1/40 vol of 1 M Na-Hepes pH 7.0, and an 
appropriate volume of NaOH. In corresponding neutral aliquots, acid, base, 
and Hepes buffer were premixed before addition. 
Quantitation of TG  F-Beta in Conditioned Media 
by Radioreceptor Assay 
TGF-beta levels in the conditioned media were determined using a two-step 
quantitative radioreceptor assay, so that any TGF-beta binding proteins that 
might be present would not score as false positives. A549 cells were seeded 
at 2  x  l0  s cells/well in 24-well cluster plates and grown for 18 h.  Cell 
monolayers were washed once with binding buffer and then incubated with 
serial dilutions of the sample to be tested in 0.2 ml/well binding buffer (see 
above). For assay of neutral or transiently acidified samples, the binding 
buffer had NaOH and HC1 added, so that the ionic strength and composition 
of the buffer was identical to that of the samples. Samples were allowed to 
bind for 2 h at 22°C, then the monolayers were washed twice with ice-cold 
binding buffer and 0.2 mi/well of a 50 pM stock of L~TGF-beta in binding 
buffer was added, for a further 2-h incubation period. Monolayers were then 
washed with ice-cold Hanks'-buffered saline containing 0.1%  BSA,  and 
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Figure  1.  Scatchard plot of TGF-beta binding to the human colon 
carcinoma  cell line HT29.  Specifically bound  (B)  and  free  (F) 
ligand were measured as described in Materials and Methods. The 
data are presented in a Scatchard plot and the inset shows TGF-beta 
binding as a function of the free ligand concentration, where the 
TGF-beta specifically bound (e) is the difference beween the total 
(o) and nonspecific (zx) binding. Each point is the mean of two de- 
terminations that generally differed by <5 %. 
bound counts solubilized as described above. TGF-beta present  in condi- 
tioned media samples was determined by comparison with a standard curve 
of purified platelet TGF-beta in the range 1-1,000 pM. The detection limits 
of the assay were 25-50 pg/0.2 ml. 
Antibodies to TGF-Beta 
Rabbits were immunized with three doses of human platelet TGF-beta cou- 
pled to keyhole limpet hemocyanin (0.1 mg TGF-beta/dose per rabbit) in 
Freund's adjuvant at 3-wk intervals. The immunoglobulin fraction was puri- 
fied by affinity chromatography on protein A-Sepharose (19). The purified 
antibodies were shown to inhibit the binding of TGF-beta to its receptor and 
neutralize TGF-beta biological activity (35). 
Results 
Distribution of TGF-Beta Receptors 
The binding of TGF-beta to more than 30 different cell lines 
and strains were assayed and the binding data were subjected 
to Scatchard ahalysis. A typical set of binding curves and 
corresponding Scatchard analysis are shown for the human 
colon carcinoma line HT29 in Fig.  1. Specific binding was 
essentially saturated by 100 pM free TGF-beta and Scatchard 
analysis gave a  linear plot characteristic of a  single high 
affinity  binding site with 13,000 receptors/ceU  and a dissocia- 
tion constant (Kd) of 17 pM. The relatively high background 
of nonspecific binding (1-5 % of input cpm) was observed for 
all cell types assayed, making it difficult  to exclude the possi- 
ble  existence of additional lower affinity sites  (Kd >  200 
pM) in some cases, since data in which the nonspecific bind- 
ing exceeded 50% of the total binding could not be analyzed 
reliably. Representative Scatchard plots for cells with low 
(1,000), intermediate (19,000), and high (81,000) numbers of 
high affinity receptors per cell are shown in Fig. 2. 
The number and affinity of the receptors for TGF-beta on 
a wide variety of different  cell types are summarized in Table 
I. Every cell type assayed expressed high affinity receptors 
for TGF-beta; these receptors were present on cells of epithe- 
lial, mesenchymal, and hematopoietic origin, on normal and 
tumor cells, on cells derived from adult and embryonic tis- 
sues, and on cells from different species (human, rodent, or 
bovine). 
Relationship between Receptor Number and Affinity 
The relationship between receptor affinity and number, for 
34 out of the 35 cell types listed in Table I, is shown in the 
double log plot of Fig. 3. Linear regression analysis revealed 
a  linear relationship between the dissociation constant Kd 
and the number of TGF-beta receptors per cell, such that 
cells with more receptors had a correspondingly lower af- 
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Figure 2. Representative Scatchard plots of TGF-beta binding to cells expressing low, intermediate, and high numbers of TGF-beta receptors 
per cell. Specifically bound (B) and free (F) ligand were determined as described in Materials and Methods.  Each point is the mean of 
two determinations that generally differed by <5 %. The cell lines represented are: (A) A2058, human melanoma line (1,000 receptors/cell); 
(B) passage 3 adult human bronchial fibroblasts (19,000  receptors/cell); (C) Swiss 3T3  mouse embryonic fibroblast line (81,000  recep- 
tors/cell). 
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Receptor on a  Wide Spectrum  of Cell Types 
TGF-Beta 
receptor 
parameters 
Cell type  Kd  No./cell 
pM 
Normal fibroblastic 
HEL 299  Human embryonic lung  28  7,000 
WI 38  Human embryonic lung  27  17,000 
Flow 2000  Human embryonic lung  13  10,000 
LL 47  Human adult lung  40  18,000 
-  Human adult lung (P3)  19  19,000 
NRK-49F  Rat kidney  40  25,000 
RAT-1  Rat embryonic  22  14,000 
FR-3T3  Rat embryonic  28  25,000 
C3H10T1/2  Mouse embryonic  60  20,000 
NIH 3T3  Mouse embryonic  26  36,000 
SWISS 3T3  Mouse embryonic  45  81,000 
AKR-2B  Mouse embryonic  16  9,000 
-  Mouse adult  47  41,000 
Normal endothelial 
-  Bovine pulmonary artery (P2)  26  9,000 
Normal mesothelial 
-  Human mesothelial (P1)  10  20,000 
Normal epithelial 
NHBE 555  Human bronchial (P3)  10  10,000 
NRK-52E  Rat kidney  5  9,000 
MMCE c17  Rat  3  1,500 
Normal hematopoietic 
-  Human tonsillar T lymphocytes  2  600 
(Concanavalin A-stimulated) 
Human tumor 
A673  Rhabdomyosarcoma  10  3,000 
A204  Rhabdomyosarcoma  41  3,000 
RD  Rhabdomyosarcoma  23  7,000 
HT1080  Fibrosarcoma  6  7,000 
DND10B67  Mesothelioma  8  6,000 
VAMT-1  Mesothelioma  2  3,000 
A2058  Melanoma  1  1,000 
FmX-II  Melanoma  38  14,500 
A549  Lung adenocarcinoma  13  10,000 
Calu I  Lung carcinoma (squamous)  7  8,000 
HUT 292  Lung carcinoma (mucoepidermoid)  1  2,000 
SW 900  Lung carcinoma (undifferentiated)  4  4,000 
T24  Bladder carcinoma  9  9,000 
A431  Cervical carcinoma  22  12,000 
HT 29  Colon carcinoma  17  13,000 
A2380  Pancreatic carcinoma  29  27,000 
The binding of J251-TGF-beta  to various cell types at 22°C was measured as 
described in Materials and Methods, and binding data were analyzed by the 
method of Scatchard (46). The passage number of low passage cultures is indi- 
cated. From repeated assays of the same cell type on different days and with 
different batches of iodinated ligand, the interassay variation was shown to be 
< +20% for the Kd of all cell types and < 5:15 % for receptor number on cell 
lines, with <+30% variation for low passage cultures of the same cell type 
from different individuals. 
finity (higher Kd). Only the human rhabdomyosarcoma line 
A204 did not obey this relationship and showed an unusual 
combination of low affinity  and low number of receptors. In- 
clusion of this cell line in the linear regression analysis re- 
duced the correlation coefficient from +0.85 to +0.77.  The 
unusual binding parameters of this cell line may explain why 
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Figure 3. Relationship between receptor affinity and the number of 
cellular receptors  for TGF-beta on normal and tumor cells.  The 
relationship between the number of TGF-beta receptors per cell and 
the dissociation constant, Ka, was determined in a double log plot 
using the data in Table I for the complete set of normal and tumor 
cells of epithelial (e) and mesenchymal or neuroectodermal  (A) 
origin.  Linear  regression analysis  revealed an  essentially linear 
relationship between the two parameters with a correlation coeffi- 
cient of +0.85. Only the human rhabdomyosarcoma line A204 (zx) 
did not obey the relationship and was not included in the regression 
analysis  (see Results). 
it appeared to have no receptors in a one-point binding assay 
(54). T lymphocytes were omitted from the linear regression 
analysis because they have a small surface area relative to 
that of the typical cell in tissue culture. 
One prediction from this relationship is that at low TGF- 
beta concentrations, all cells will bind approximately the 
same number of TGF-beta molecules per cell. The data in 
Fig. 4  show that in the range of concentrations for which 
TGF-beta is normally physiologically active (0.1-10 pM), a 
representative  selection of human cell  lines  with  widely 
differing TGF-beta binding parameters do indeed bind ap- 
proximately the same number of TGF-beta molecules per 
cell at any given TGF-beta concentration. Again, the rhab- 
domyosarcoma line A204 is a notable exception, binding at 
least 10-fold less TGF-beta at any given ambient TGF-beta 
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Figure 4.  All cell types (except A204) bind essentially the same 
number of TGF-beta molecules per cell at low TGF-beta concentra- 
tions. The specific binding of TGF-beta to its cellular receptors was 
determined for a series of human cells with widely differing recep- 
tor properties  (see key)  as described  in Materials  and  Methods. 
Each point is the mean of two determinations that differed by <5 %. 
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Figure 5. Binding of low concentrations of TGF-beta to A549 hu- 
man lung adenocarcinoma cells: lack of evidence for "super-high" 
affinity sites. The sensitivity of the standard binding assay was in- 
creased 6-8-fold by seeding cells at 5  x  l05 cells/well in 6-well 
cluster dishes and using high specific activity (4 ~tCi/pmol) t25I- 
TGF-beta. Each point is the mean of two determinations differing 
by <10%. The amount of ligand specifically bound (e) is the differ- 
ence between the total (o) and nonspecific (zx) binding, and ranged 
from 125 cpm/weU to 6,000 cpm/weU over the range of free TGF- 
beta concentrations from 50 fM to 5 pM. 
concentration. The very different binding properties of this 
one line make it unlikely that the similar levels of binding 
seen in the other cell types are merely an assay artifact, since 
assay conditions were essentially identical for all cell types. 
Relationship between Ligand Binding and 
Biological Response 
For a number of cell types, the half-maximal biological effect 
of TGF-beta is observed at a much lower concentration of 
TGF-beta than that required to half-saturate the receptor. 
Thus TGF-beta inhibits  DNA  synthesis in normal human 
bronchial epithelial cells half-maximally at 0.4 pM  (35), 
while the receptor has a  Kd of 10 pM,  and similarly,  the 
receptor on the lung adenocarcinoma line has a  Kd of 13 
pM,  whereas  TGF-beta inhibits the growth of these cells 
half-maximally at 0.4 pM  (40).  The possible existence of 
previously undetected "super-high" affinity binding sites that 
might  mediate this  biological response was  tested  for in 
A549 cells,  using higher specific activity t25I-TGF-beta (4 
IxCi/pmol) and increased numbers of cells, to increase the 
sensitivity of  the assay ~6-8-fold. The results in Fig. 5 show 
no indication of a saturable higher affinity site in the range 
of free TGF-beta concentrations from 50 fM to 5 pM.  Ex- 
trapolation of  the Scatchard curve obtained from this binding 
data shows the binding detected corresponds to a receptor 
with a Kd of "18 pM, and 11,000 sites/cell (data not shown), 
which is the same class of binding sites as is detected under 
less sensitive conditions. Since the more sensitive conditions 
would allow detection of <200 receptors/cell, if a higher af- 
finity receptor is present it must represent <2 % of the total 
receptor population. While this possibility cannot be ruled 
out, it seems likely that the receptor identified by these bind- 
ing assays is the one that mediates the biological response, 
and that maximum biological response to TGF-beta may be 
elicited at 10-50% receptor occupancy. However, it should 
be noted that the time-scale and culture conditions are often 
very different for the binding and biological assays, and that 
this may be a source of some of  the discrepancy. Full biologi- 
cal response at fractional receptor occupancy has also been 
observed for EGF and insulin (1, 25). 
Modulation of the TGF-Beta Receptor by 
Heterologous Agents 
Many of the agents that modulate EGF/TGF-alpha action act 
by altering the affinity or number of available EGF receptors 
(3,  8, 22,  31, 45).  The possibility that various factors that 
enhance or antagonize TGF-beta action might similarly act 
through effects on the TGF-beta receptor was explored. The 
data in Table II show that none of the agents tested, including 
other growth factors, retinoic acid, phorbol esters, or epi- 
nephrine,  had an appreciable effect on TGF-beta binding, 
even through they all modulate the response of the various 
target cells to TGF-beta. 
Effects of Transformation on TGF-Beta 
Receptor Properties 
The effects of  in vitro transformation by various agents on the 
specific binding of TGF-beta to its cellular receptor were de- 
termined for matched pairs  of normal and in vitro trans- 
formed cells (Fig. 6). Transformation appeared to affect the 
TGF-beta receptor in one of two ways; retroviral infection 
and transfection with certain viral oncogenes caused a de- 
crease in binding of TGF-beta to its receptor, whereas trans- 
formation by the DNA virus SV-40 and chemical transforma- 
tion resulted in increased binding of TGF-beta. Scatchard 
analyses of these data (Table UI) revealed that the effect was 
primarily on the number of  TGF-beta receptors per cell, with 
little significant change in the receptor affinity, except in the 
case of the ethylnitrosourea-treated MMCE cells where a 
3.7-fold decrease in receptor affinity was observed on trans- 
formation. However, in no case was TGF-beta binding al- 
tered by more than 2-3-fold, which is in marked contrast to 
the dramatic decrease in or total loss of assayable TGF-alpha/ 
EGF or PDGF receptors seen on transformation (9,  53). 
The rates of secretion of TGF-beta by a number of different 
human tumor cells,  in vitro transformed rodent cells and 
their untransformed counterparts were determined, and com- 
pared with the number of TGF-beta receptors expressed by 
these cells (Table IV). It is apparent that there is no simple 
correlation between levels of TGF-beta secretion, and the 
number of receptors on the cells. For example, of the three 
rhabdomyosarcoma lines  assayed,  the  RD  line which  se- 
creted 2.5 times more TGF-beta than the A673 line and over 
26 times more than the A204 line on a per cell basis never- 
theless expressed more than twice as many receptors as ei- 
ther of these two lines. Thus the different numbers of recep- 
tors expressed on the various cell types are probably not due 
to varying degrees of receptor down-regulation in response 
to endogenously secreted TGF-beta. 
Similarly, the data in Table V show that growth of  Moloney 
sarcoma virus (MoSV) transformed NRK cells (536-MSV) 
for 24 or 48 h in the presence of 100 lxg/ml of the immuno- 
globulin fraction of an anti-TGF-beta antiserum (sufficient to 
neutralize binding and biological activity of 300 pM TGF- 
beta) had essentially no effect on the level of specific binding 
of  TGF-beta to the cells at the end of  this period. It is possible 
that endogenous TGF-beta produced by these cells could be 
causing receptor down-regulation from an immunologically 
inaccessible  site,  or  that  receptor resynthesis  could  take 
longer than 48 h. However, it seems likely that the decreased 
receptor number seen in these and other cell types on trans- 
formation is not a  result of increased TGF-beta secretion 
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Binding of TGF-Beta  to Its Cellular  Receptor 
Effect on 
Cell  Agent  Biological effect (ref.)  TGF-Beta Binding 
NRK  EGF  Required for TGF-beta to induce colony  <20% Decrease 
formation in soft agar (4) 
NRK  PDGF  Required for TGF-beta to induce colony  NE 
formation in soft agar (4) 
NRK  Retinoic acid  Sensitizes cells to TGF-beta-induced colony  <10% Decrease 
formation (8 x  decrease in EDs0 for 
TGF-beta) (39) 
Inhibits TGF-beta-induced colony 
formation by up to 50%* 
Inhibits colony formation in response to 
PDGF +  TGF-beta (but not in response 
to EGF) (42) 
Inhibits TGF-beta-induced squamous 
differentiation (35) 
NRK  TPA  <10%  Decrease 
Myc-1  Retinoic acid  NE 
NHBE  Epinephrine  NE 
Cells were grown for 1--4  d in their normal growth media (see Materials  and Methods), in 24-well  cluster plates with or without  addition  of the agents listed above, 
and 1251-TGF-beta  binding was determined  over a range of concentrations  from 1-200 pM and normalized for differences in cell number for the different treat- 
ments. Concentrations  of the reagents were as follows: EGF, 1 nM; retinoic acid, 1 BM; TPA, 100 ng/ml; epinephrine, 1.6 BM, Retinoic acid and TPA were 
added in dimethylsulfoxide  (final concentration,  0.1%). Control experiments  confirmed  that dimethylsulfoxide  itself had no effect on TGF-beta binding. For the 
experiment  comparing  TGF-beta binding to NRK cells in the presence and absence  of PDGF, cells were grown either in DME containing 10% platelet-poor  calf 
plasma (for the no PDGF condition) or in DME containing 10% autologous  calf serum (+ PDGF condition). The 10% calf serum was estimated to contain ,x,3 
ng/ml PDGF since addition of this amount of PDGF to the autoiogous  platelet-poor  plasma restored the full response of the NRK cells to EGF and TGF-beta 
that was seen in the presence of the calf serum (4). Abbreviations  used are as follows: NRK, normal rat kidney fibroblast;  Myc-1, Fischer rat 3T3 fibroblast  trans- 
fected with c-myc oncogene; NHBE, normal human bronchial epithelial cells; TPA, 12-O-tetradecanoylphorbol-13-acetate;  NE, no effect. 
* A. B. Roberts, personal communication. 
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Figure 6. The effect of transformation by various agents on specific 
binding of TGF-beta to its cellular receptors. The specific binding 
of TGF-beta to its cellular receptors was determined as described 
in Materials and Methods for a number of matched pairs of normal 
and transformed cell types in culture. In each case, binding to the 
normal cell is represented by closed circles (e) and binding to the 
corresponding transformed cells by open symbols (o) (zx). HaSV 
is the Harvey sarcoma virus. NEO, Myc-1, and EJ are Fischer rat 
3T3 lines transfected respectively with a neomycin marker alone, 
or with this marker plus the c-myc or H-ras oncogene from the EJ 
human bladder carcinoma line. WI38 VA13 is an SV-40 transfor- 
mant of the human embryonic lung fibroblast WI38 and MMCE 
ENU is an ethylnitrosourea-induced  transformant of a rat epithelial 
cell. Each point is the mean of two determinations. 
causing  receptor  down-regulation,  as  had  been  suggested 
previously (2),  but due to some other effect of transforma- 
tion.  Particle size analysis using a  Coulter counter showed 
that  the  median  cell  volume  of  Harvey  sarcoma  virus 
(HaSV)-transformed  NIH  3T3  cells  (2.0  x  103  ixm  3)  was 
greater  than  that  of the  normal  parent  (1.5  x  103  gm3), 
eliminating the possibility for these cells that the decreased 
number of receptors  on the transformed cell was  due to a 
transformation-induced change in cell size. Thus the mecha- 
nism of the small transformation-induced changes in TGF- 
beta binding remains obscure. 
Ligand-induced Down-Regulation of the TG  F-Beta 
Receptor in Transformed Cells 
A549  cells were  exposed  to  20 pM  adcied human platelet 
TGF-beta for 2 h at 37°C to allow any ligand-induced recep- 
tor internalization to occur.  After extensive washing over a 
further 2-h period  at 37°C to  dissociate  any cell  surface- 
associated TGF-beta that had not been internalized (control 
experiments showed this procedure removed 93 %  of TGF- 
beta on the cell  surface),  the residual binding capacity  of 
these cells for TGF-beta was determined at 22°C, a tempera- 
ture at which no further down-regulation occurs  (data not 
shown).  This residual binding capacity was then compared 
with that of cells that had not been previously exposed  to 
TGF-beta (Table VI). It can be seen that pre-exposure of the 
A549 cells to exogenous TGF-beta results in down-regula- 
tion of a  substantial fraction (~70%)  of the receptors  that 
were occupied during this pre-incubation period.  However, 
not all tumor-derived cells can down-regulate their recep- 
tors; the human rhabdomyosarcoma line RD and the MoSV- 
transformed NRK line 536-MSV did not show any receptor 
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TGF-Beta  Receptor Properties 
TGF-Beta 
Receptor 
Parameters 
Cell Type  Kd  No./ceU 
pM 
Retrovirus infection 
NIH 3T3  Mouse fibroblast  23  36,000 
HaSV-NIH  3T3  HaSV  infected  31  17,000 
NRK  Rat kidney fibroblast  36  31,000 
536-MSV  MoSV  infected  36  21,000 
Oncogene transfection 
Fischer rat 3T3 cells 
NEO  Neomycin transfectant  28  25,000 
MYC-1  Myc transfectant  18  12,000 
EJ  H-ras transfectant  24  12,000 
DNA virus infection 
WI38  Human embryonic lung fib.  27  17,000 
WI38VA13-2RA  SV-40 infected  36  21,000 
Chemical transformation 
MMCE C1#7  Rat epithelial cell  3  1,500 
MMCE ENU C1#6  Ethylnitrosourea-treated  11  4,100 
C3H10TI/2  Mouse fibroblast  60  20,000* 
MCA C1#6  Methylcholanthracene-treated  80  32,000* 
The specific binding of TGF-beta to its cellular receptors was determined as 
described in Materials and Methods for matched pairs of non-neoplastic and 
transformed cell  types in culture,  and the binding data  were  subjected to 
Scatchard analysis. The two cell lines marked with an asterisk showed some 
indication of a class of higher affinity receptors that were unaffected by trans- 
formation.  Interassay  variation  was  typically  <+20%  for  both  binding 
parameters. 
down-regulation induced by TGF-beta, and even the A549 
cells when exposed to saturating concentrations of TGF-beta 
(400 pM) only down-regulated the same number of  receptors 
(,~3,000/cell) as were down-regulated by exposure to low lev- 
Table V. Effect of  Prolonged Exposure to Anti-TGF-Beta 
Antibody on Growth of  a MoSV-Transformed NRK Cell 
Line (536 MSV) and Its Ability to Bind TGF-Beta 
Growth conditions 
No. ceils  TGF-beta 
per well  %  specifically  % 
x  1@  Control  bound  Control 
fmol/lO  6 cells 
No additions  1.25  +  0.01  "100"  14.3  +  0.3  "100" 
+  Anti-TGF-beta IgG  1.26  +  0.01  101  14.5  +  0.3  101 
+  Normal rabbit IgG  1.24  -1- 0.04  99  14.3  +  0.2  100 
536 MSV cells were seeded at 2  ×  liP cells/well in DME containing 5% 
FBS, and allowed to grow for 24 h. Growth medium was then removed and 
replaced  with  the  same medium containing either  100  ~tg/ml  of the  im- 
munoglobulin (IgG) fraction of anti-TGF-beta antiserum or normal rabbit se- 
rum. A control with no IgG added was also included. After a  further 24-h 
incubation, TGF-beta binding was assayed by addition of 50 pM  ~z~I-TGF- 
beta with or without 10 nM unlabeled TGF-beta, as described in Materials and 
Methods. The results are the mean +  SD of three determinations. Essentially 
similar results were obtained if the cells were exposed to antibody for 48 h 
rather than 24 h. 
els of TGF-beta (data not shown).  We have demonstrated 
similar  partial  down-regulation  for  nontransformed cells 
(17). Thus even cells that can down-regulate their receptor 
do not do so extensively. Given that full biological response 
can be observed at partial receptor occupancy, down-regula- 
tion of <50 % of the total receptors may not affect the ability 
of the cell to respond to the ligand, unless the biological re- 
sponse is mediated by a subpopulation of receptors that are 
indistinguishable from the rest in terms of their equilibrium 
binding characteristics, and it is this subpopulation that is 
down-regulated. 
The Latent Form of TGF-Beta Does Not Bind 
to the Receptor 
A latent form of TGF-beta that is only biologically active af- 
ter acidification has been demonstrated in the neutral condi- 
Table IV. Lack of Correlation between Levels of TGF-Beta Secretion and Number of 
TGF-Beta Receptors on Normal and Transformed Cells 
[TGF-beta]  in  Rate of 
Cell type  conditioned medium  TGF-beta secretion  TGF-beta receptors 
pM  pg/lO  6 cells per 24 h  No./cell 
Normal human 
NHBE  (Bronchial epithelial) 
Human tumor 
A549  (Lung adenocarcinoma) 
A2380  (Pancreatic carcinoma) 
A2058  (Melanoma) 
A204  (Rhabdomyosarcoma) 
A673  (Rhabdomyosarcoma) 
RD  (Rhabdomyosarcoma) 
Rodent 
Fischer rat 3T3 cells 
Neo  (Neomycin transfectant 
Myc-I  (Myc transfectant) 
EJ  (H-ras transfectant) 
MMCE c1#7  (Rat epithelial) 
MMCE ENU  (Chemical transformant) 
2.0  275  10,000 
33.0  625  10,000 
0.003  0.5  27,000 
1.8  50  1,000 
0.3  40  3,000 
35.0  390  3,000 
28.0  990  7,000 
0.8  240  25,000 
9.0  230  12,000 
63.0  555  12,000 
8.0  245  1,500 
11.0  430  4,000 
TGF-beta concentrations were determined for acid-dialyzed, concentrated conditioned media using a quantitative radioreceptor assay as described in Materials 
and Methods. The number of TGF-beta receptors per cell  was determined from Scatchard analysis of binding data as in Table I. 
Wakefield et al. Distribution  and Modulation  t~f TGF-Beta Receptor  971 Table VI. Down-Regulation of TGF-Beta Receptors on A549 Human Lung Carcinoma Cells 
TGF-beta  No.  occupied 
specifically  receptors 
Experiment  Conditions  bound  per cell 
fmol/lO  6 cells 
A  No.  receptors occupied in presence  Cells exposed to 20 pM  t25I-TGF-beta  6.68  ±  0.06  4,020  ±  40 
of 20 pM TGF-beta  for 2 h at 22°C 
B  Total No. of assayable receptors  Cells exposed to 500 pM  z~I-TGF-  11.88  ±  1.19  7,150  +  720 
beta (saturating)  for 2 h at 22°C 
C  Total No. of assayable receptors  Cells pre-exposed to 20 pM unlabeled  6.60  ±  0.81  3,970  ±  490 
after pre-exposure to 20 pM TGF-beta  TGF-beta for 2 h at 37°C,  washed 
for 2  h at 37°C, and exposed to 
500 pM 125I-TGF-beta for 2 h at 
22°C 
Cells pre-exposed to 20 pM  mI-TGF- 
beta for 2 h at 37°C and then 
washed for 2 h at 37°C 
D  No.  of receptors remaining occupied 
after pre-exposure to 20 pM TGF-beta 
and washing 
E  No. of receptors down-regulated by 
exposure to 20 pM TGF-beta 
0.44  ±  0.03  270  ±  20 
B  -  (C  +  D)  4.84  2,910 
A549 cells were seeded at  1.5  x  105 cells/well in 24-well cluster plates and allowed to grow for 24 h. The extent of down-regulation of the TGF-beta receptor 
in response to pre-exposttre of the cells to 20 pM unlabeled TGF-beta was then determined as detailed in the table. The determination of the number of receptors 
remaining occupied after pre-exposure  to 20 pM TGF-beta and washing (step D above) allowed elimination of the possibility that apparent down-regulation was 
simply due to persistence of bound TGF-beta from the preincubation period. 
tioned media of a number of different cell types (26, 27, 38). 
We therefore examined the possibility that this biologically 
latent form might be unable to bind to the receptor. Condi- 
tioned medium was collected from A549 ceils under neutral 
conditions and assayed by a competitive radioreceptor assay, 
with and without transient acidification to pH 3.2 with HCI, 
as  described  in  Materials  and  Methods.  The  results  are 
shown in Fig.  7.  The neutral conditioned medium did not 
compete for binding to the TGF-beta receptor at any concen- 
I  r 
100' 
0 i~,  J 
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T  I  I 
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Figure 7. Determination of TGF-bota concentration in neutral and 
acidified conditioned media from A549 cells using a quantitative 
radioreceptor assay. Neutral  serum-free conditioned medium was 
collected from A549 cells and aliquots were prepared for assay with 
or without transient acidification and reneutralization as described 
in Materials and Methods.  The concentration of TGF-beta in the 
conditioned media samples was then determined in a quantitative 
radioreceptor assay, using A549 cells as the indicator cell, as de- 
tailed in Materials and Methods. Bound counts were normalized as 
a percent of the counts bound in control wells (10,480 +  240 cpm) 
after subtraction  of counts  bound  in the  presence  of an excess 
(10 nM) of unlabeled TGF-beta (2,670 cpm). The samples were as 
follows: human platelet TGF-beta standard (e); neutral A549 con- 
ditioned medium (,x); transiently acidified A549 conditioned medi- 
um, with no further treatment  (&), or preincubated at 4°C over- 
night with  100 pg/ml of the immunoglobulin  fraction  of normal 
rabbit serum (n) or anti-TGF-beta antiserum  (m). 
tration tested. In contrast, transient acidification followed by 
reneutralization resulted in high levels of competing activity. 
Addition of an excess of anti-TGF-beta antibody neutralized 
at least 83 % of the competing activity, suggesting that the 
majority of the competing activity was due to TGF-beta or 
a closely related protein. The latent form was biologically in- 
active as determined by its inability to induce the growth of 
NRK cells in soft agar in the presence of EGF without prior 
acidification (data not shown). 
Similar assays on the  neutral  conditioned  media of ten 
other transformed or tumor-derived cell lines (B16F1, mouse 
melanoma; A375 and A2058, human melanomas; A673 and 
RD, human rhabdomyosarcomas; HTI080, human fibrosar- 
coma; A431,  HT29, and HUT292, respectively, human vul- 
var, colon, and lung carcinomas: and 536-MSV, an MoSV- 
transformed NRK cell) and one normal cell type (normal 
human bronchial epithelial cells), showed that all these cells 
also secrete TGF-beta in a latent form (data not shown). Thus 
it appears to be a  common property of all cells to secrete 
TGF-beta in a form that cannot bind to the receptor without 
prior activation. This could partly explain the lack of recep- 
tor down-regulation by endogenously secreted TGF-beta in 
cell types, such as A549 cells, that retain the ability to down- 
regulate their receptors in response to exogenously added 
platelet TGF-beta. 
Discussion 
In this paper, the distribution and modulation of the cellular 
receptor for TGF-beta on a wide variety of cell types were 
examined and the results, which are considered in detail be- 
low, give an insight into possible mechanisms of control of 
TGF-beta action. 
The data show universal expression of a  single class of 
high affinity receptors for TGF-beta on all cell types assayed 
to  date,  from both  normal  and  neoplastic  sources.  This 
makes the distribution of the TGF-beta receptor even more 
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on hematopoietic cells, and suggests that all cell types may 
be potential targets for TGF-beta action. Partial occupancy 
(10-50%)  of this receptor class appears to be sufficient to 
give full biological response, since there was no evidence for 
the existence of  yet higher affinity receptor classes. However, 
due to the high nonspecific binding of the ligand, the exis- 
tence of lower (Kd <  200 pM) affinity receptors could not 
be ruled out in some cases, and further studies will be neces- 
sary to determine how the binding sites identified by these 
equilibrium binding  studies  relate to  the  three  structural 
classes of receptor identified by Cheifetz et al. in chemical 
cross-linking studies (12). 
The breadth of  the present study allowed us to demonstrate 
a novel inverse relationship between the affinity of the TGF- 
beta receptor and the number of receptors expressed per cell 
on the various normal and tumor cell types assayed (Fig. 3), 
which has not been observed for any other growth factor 
receptor. This relationship suggests a remarkable conserva- 
tion of the degree of ligand binding, with all cell types bind- 
ing approximately the same number of TGF-beta molecules 
per cell at physiological TGF-beta concentrations. Presum- 
ably TGF-beta binding triggers a response that must be very 
tightly controlled in its degree. 
Given the bidirectional effects of TGF-beta on cell growth 
(40,  55),  it was possible that normal cells might become 
transformed either by loss of functional receptors for TGF- 
beta in the instances where TGF-beta is growth inhibitory, 
or by overexpression of TGF-beta receptors  in cell types 
where TGF-beta stimulates growth (50). However, in no case 
was a tumor-derived cell line found to have lost all receptors, 
nor were there tumor cells expressing exceptionally high 
numbers of receptors. The human melanoma line A2058 had 
only 1,000 receptors/cell but was strongly growth-inhibited 
by TGF-beta (40), indicating that only a very low number of 
receptors are required to mediate a biological effect, and that 
a low number of TGF-beta receptors per se does not prevent 
the  cell  responding.  However,  the human rhabdomyosar- 
coma line A204 expressed an unusual combination of low af- 
finity and low number of receptors such that it bound 10-fold 
less TGF-beta per cell than other cell types assayed. Since 
these cells do not respond to TGF-beta (data not shown), they 
may be functionally receptorless, and it is possible that this 
feature contributes to the uncontrolled proliferation of these 
cells. With the exception of this case, there is no simple rela- 
tionship between binding parameters and the type or direc- 
tion of the biological response of tumor cells to TGF-beta. 
Thus, unlike the more limited data of Tucker et al. (54), the 
present  results  do  not  indicate  any  correlation  between 
receptor numbers on tumor-derived cell lines that grow well 
in  soft agar (A673, A204,  RD,  Calu I,  HT  29,  FmX II, 
HT1080)  and those that grow poorly (A549,  DND10B67, 
T24, A431), nor between receptor parameters and the direc- 
tion of effect  of TGF-beta, be it stimulatory (DND10B67),  in- 
hibitory (A549, HT1080, A2058), or no effect at all (Calu I, 
FmX II, HT29,  and A673). 
Not only is the degree of TGF-beta binding highly con- 
served between cell types, but TGF-beta binding to any given 
cell type is essentially unaffected  by agents that affect the bio- 
logical action of TGF-beta in that cell.  This suggests that 
modulation of binding  may not be  an  important control 
mechanism in the action of this growth factor, but rather that 
the cellular response may be modulated at subsequent steps. 
This is in direct contrast to the situation with TGF-alpha 
and EGF, since a wide number of agents, including PDGF, 
fibroblast growth factor, TGF-beta, phorbol esters, and reti- 
noic acid, change the number or affinity of the TGF-alpha/ 
EGF receptor, thereby altering the cellular response to these 
growth factors (3, 8, 22, 31, 45).  Equally, TGF-beta causes 
only minimal (<50%)  down-regulation of its receptor in 
most cell types, and the TGF-beta receptor is relatively un- 
affected  (<2-3-fold  changes)  by  cellular  transformation. 
Again this is marked contrast to the dramatic decrease or to- 
tal disappearance of assayable receptors for TGF-alpha/EGF 
or PDGF that occurs on transformation of many cell types 
(9, 53), and which, for PDGF, has been attributed to receptor 
down-regulation due to increased secretion of PDGF-like 
proteins (9,  18, 20). While this work was in progress, Mas- 
sagu6 and Kelly (33) published data suggesting that the lack 
of apparent down-regulation of the TGF-beta receptor in 
BALB/c 3T3 fibroblasts is due to rapid recycling of  the recep- 
tor after ligand-induced internalization, or rapid replenish- 
ment of surface receptors from a  large intracellular pool. 
Presumably similar mechanisms may operate in other cell 
types, and may account for the lack of correlation between 
levels of secreted TGF-beta and the number of receptors ex- 
pressed by cells analyzed in the present work. Thus, at least 
in cell culture, expression of the TGF-beta receptor appears 
to be constitutive as well as universal. 
Extractable TGF-beta has been found in all normal and tu- 
mor tissues assayed to date (43).  Since the receptor seems 
to be universally expressed, this would suggest that all cells 
are potentially in a continual state of autocrine or paracrine 
regulation by TGF-beta. However,  we have confirmed and 
extended the finding (26, 27, 38) that cells appear to secrete 
TGF-beta in a biologically inactive form, and we have dem- 
onstrated that this latent TGF-beta cannot bind to the recep- 
tor. This allows some target specificity to be introduced into 
the system, since only cells capable of activating the latent 
form of TGF-beta will be responsive. Thus, activation of la- 
tent TGF-beta to a form that can bind to the receptor is proba- 
bly an important extracellular regulatory point in TGF-beta 
action. This raises the possibility that the tumorigenic lesion 
in some carcinoma cells may be loss of the abillty to activate 
latent autocrine TGF-beta, such that these cells can no longer 
limit their own growth; the evidence to date suggests that epi- 
thelial cells are always inhibited by the peptide (11, 35, 37, 
40, 49, 55). Preliminary experiments (Wakefield, L. M., and 
T. Masui, unpublished observations) suggest that normal hu- 
man bronchial epithelial cells can activate and respond to the 
TGF-beta that they secrete,  while the human lung adeno- 
carcinoma line A549 has lost the ability to activate latent 
TGF-beta. 
It has been suggested that some positive autocrine growth 
factors may interact with their receptors in the Golgi appara- 
tus or secretory vesicles, thus generating an intracellular au- 
tocrine loop (7, 20).  One important aspect of the secretion 
of TGF-beta in a latent form that cannot bind to the receptor 
may be that it would force the TGF-beta autocrine regulatory 
loop to operate extracellularly, by preventing premature in- 
teraction of the ligand with its receptor in the Golgi appara- 
tus. This would potentially make growth regulation by TGF- 
beta  subject to  modulation by agents  in  the extracellular 
space, giving increased opportunity for communication with 
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the receptor does not appear to be modulated by any of the 
agents  tested,  this type  of communication  between  cells 
would probably have to be at the level of activation of the la- 
tent form of TGF-beta. The nature of the latent form and the 
in vivo mechanism of activation that is mimicked by acidifi- 
cation in vitro are currently being investigated (Wakefield, 
L.  M.,  D.  M.  Smith,  K.  C.  Flanders, and M.  B.  Sporn, 
manuscript in preparation). 
In conclusion,  we have shown that the TGF-beta receptor 
is universally  expressed  and is strongly  functionally  con- 
served, such that all cell types bind the same number of TGF- 
beta molecules per cell at physiological TGF-beta concentra- 
tions.  Binding to the receptor is not modulated by agents 
affecting TGF-beta action and, compared with the receptors 
for other growth factors, TGF-beta binding is only slightly 
affected by the ligand itself and by transformation, confirm- 
ing the pronounced conservation of binding. Finally we have 
shown  that the  biologically  inactive  form  of  TGF-beta 
secreted by various cell types is unable to bind to the receptor 
without prior activation, and we suggest that this may pre- 
vent  premature association  of ligand  and  receptor in  the 
Golgi apparatus or secretory vesicles. 
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